WebDoctor Encyclopedia

Chronic myeloid & MDS Lymphomas

Follicular dendritic cell sarcoma

Follicular dendritic cell sarcoma is a rare cancer of the support cells in lymph node follicles. It usually affects adults, often in neck lymph nodes, the tonsil or abdomen, and is mainly treated with complete surgery, sometimes followed by radiotherapy.

Medically reviewed Last reviewed October 17, 2026

What is follicular dendritic cell sarcoma?

Follicular dendritic cell sarcoma (FDC sarcoma) is a rare cancer that grows from follicular dendritic cells. These are support cells found in the B-cell follicles of lymph nodes and other lymphoid tissue. Their normal job is to hold on to antigens (pieces of germs) and show them to B cells, helping the immune system make antibodies.

Despite the similar name, follicular dendritic cells are not true immune blood cells. They develop from connective tissue (stromal) cells. For this reason, the latest WHO classification places FDC sarcoma among the stroma-derived tumours of lymphoid tissues (Alaggio et al., 2022).

FDC sarcoma usually affects adults in middle age, with an average age of about 45-50 years. Men and women are affected about equally (Saygin et al., 2013).

About a third of tumours start in lymph nodes, most often in the neck. The rest grow outside lymph nodes, for example in the tonsil, throat, bowel, liver, spleen or the middle of the chest (mediastinum).

A special form, now called EBV-positive inflammatory follicular dendritic cell sarcoma, grows in the liver or spleen. It is linked to the Epstein-Barr virus and mainly affects women.

FDC sarcoma is usually treated with surgery, sometimes followed by radiotherapy. It often behaves like a low- to intermediate-grade sarcoma: it can come back and spread, but many people live for years (Chan et al., 1997).

1. Key facts at a glance

Feature Details
Type of cancer Sarcoma of follicular dendritic (stromal) cells of lymphoid tissue
How common Very rare; a few hundred cases described in the medical literature
Typical age Adults; average about 45-50 years
Common sites Neck lymph nodes, tonsil, throat, gut, liver, spleen, mediastinum
Key markers CD21, CD23, CD35, clusterin, CXCL13
Linked conditions Hyaline vascular Castleman disease in some cases; EBV in the inflammatory type
Main treatment Complete surgical removal, often with radiotherapy
Typical spread Local recurrence; lymph nodes, lungs, liver
Outlook Many people do well after complete removal; recurrence is common

2. Causes and risk factors

The cause of FDC sarcoma is not known in most people. It is not inherited and not contagious.

Factor Notes
Castleman disease Hyaline vascular (unicentric) Castleman disease is found in or near some tumours and may be a precursor
Epstein-Barr virus (EBV) Found in the tumour cells of the inflammatory form in the liver and spleen
Sex The EBV-positive inflammatory type is more common in women
Geography The EBV-positive inflammatory type is reported more often in East Asia

Gene changes

FDC sarcomas often carry changes in genes that control the NF-kappaB pathway, a signalling system involved in inflammation and cell survival. Common changes involve NFKBIA, CYLD and TNFAIP3, and many tumours lose the CDKN2A tumour suppressor gene (Griffin et al., 2016).

A minority carry the BRAF V600E mutation. These changes arise only in the tumour and are not passed on in families.

FDC sarcoma and Castleman disease

In a minority of cases, often quoted as about 1 in 10 to 1 in 5, the tumour occurs together with hyaline vascular Castleman disease, a non-cancerous overgrowth of lymph node tissue (Facchetti et al., 2021). Abnormal clusters of follicular dendritic cells in Castleman disease may, in rare cases, develop into FDC sarcoma.

The EBV-positive inflammatory type

This form looks and behaves differently from classic FDC sarcoma.

Feature EBV-positive inflammatory type Classic FDC sarcoma
Main sites Liver and spleen Lymph nodes, tonsil, gut and other sites
Sex Mostly women Men and women equally
Microscope Scattered tumour cells among many inflammatory cells Sheets and whorls of tumour cells
EBV in tumour cells Present Absent
Behaviour Usually slow-growing Low to intermediate grade

3. How does it look

The lump

Feature Description
Lymph node tumours A painless, slowly growing lump, usually in the neck
Tonsil and throat A mass on one side of the throat
Abdominal tumours A large mass in the bowel wall, mesentery, liver or spleen
Size Often 5 cm or more; abdominal tumours can be much larger
Edges Usually well defined, but may grow into nearby tissue
Cut surface Pink-tan, firm; sometimes with bleeding or dead areas in large tumours

On scans

On CT or MRI, FDC sarcoma usually appears as a solid, well-defined mass that takes up contrast dye. Large tumours may have areas of dead tissue or calcium. On PET-CT, the tumour usually lights up. These findings are not specific, so a biopsy is needed.

Under the microscope

Feature Description
Cells Oval to spindle-shaped cells with pale pink cytoplasm and indistinct borders
Nuclei Oval, with fine chromatin and small nucleoli; some cells have two nuclei
Pattern Whorls, fascicles (bundles) and storiform (cartwheel-like) arrangements
Background Small lymphocytes scattered among the tumour cells, often clustered around blood vessels
High-grade features Marked nuclear atypia, many mitoses and necrosis in more aggressive tumours

Special stains

Marker Result
CD21, CD23, CD35 Positive (classic follicular dendritic cell markers)
Clusterin, CXCL13, podoplanin (D2-40) Often positive
SSTR2 Often positive
CD1a and langerin Negative
Keratin Usually negative
EBV (EBER) Positive in the inflammatory type of liver and spleen

FDC sarcoma is often misdiagnosed at first, because it can look like other spindle-cell tumours, thymoma, carcinoma or lymphoma (Facchetti et al., 2021).

4. Symptoms

Many people have few symptoms and notice only a slowly growing lump.

Common symptoms

  • A painless lump in the neck, armpit or groin
  • A lump on one side of the throat or a feeling of something stuck
  • Difficulty swallowing or a muffled voice with tonsil tumours
  • Tummy pain, fullness or a lump in the abdomen
  • Tiredness

General symptoms

Some people, especially those with abdominal or EBV-positive tumours, develop:

  • Fever
  • Weight loss
  • Night sweats
  • Anaemia, causing tiredness and breathlessness

Symptoms of spread

Site Possible symptoms
Lymph nodes New swollen glands
Lungs Cough, breathlessness, chest pain
Liver Pain under the right ribs, jaundice (rare)
Abdominal lining Swelling of the tummy, bloating

Rare immune problems

FDC sarcoma, particularly when linked with Castleman disease, can rarely be associated with paraneoplastic pemphigus, a severe blistering disease of the mouth and skin, and with myasthenia gravis, which causes muscle weakness.

When to seek medical advice

See a doctor if you have a lump that lasts more than 2-3 weeks, a growing throat or neck mass, or unexplained fever and weight loss.

5. Diagnosis

Test Purpose
Examination Checks lymph nodes, throat and abdomen
Ultrasound, CT or MRI Shows the size and position of the mass
Biopsy A surgical (excision) biopsy or core biopsy; needle aspiration alone is rarely enough
Immunohistochemistry CD21, CD23, CD35 and other markers confirm the diagnosis
EBV testing (EBER) For liver and spleen tumours
PET-CT Staging, to find other sites of disease
Blood tests Blood count, liver and kidney function

Because the tumour is rare and easily confused with other cancers, the sample should be reviewed by an expert haematopathologist or sarcoma pathologist.

Conditions that can look similar

Condition How it differs
Interdigitating dendritic cell sarcoma S100 positive; CD21 and CD23 negative
Histiocytic sarcoma CD163 and CD68 positive; FDC markers negative
Thymoma Keratin positive epithelial cells
Gastrointestinal stromal tumour KIT and DOG1 positive
Inflammatory myofibroblastic tumour ALK often positive; FDC markers negative
Lymphoma B- or T-cell markers positive

6. Treatment

Treatment is planned by a team with experience in rare lymphoid and sarcoma tumours.

Localised disease

Treatment Notes
Surgery Complete removal with clear margins is the main treatment
Radiotherapy Often given after surgery for large tumours, close margins or high-grade features
Chemotherapy after surgery Not of proven benefit; sometimes considered for high-risk tumours

In pooled analyses, people whose tumours were completely removed did best (Saygin et al., 2013). The benefit of added radiotherapy or chemotherapy has not been proven in trials, so the decision is made case by case.

Advanced or recurrent disease

Treatment Notes
Surgery for recurrence Repeat surgery can control local recurrences or single metastases
Chemotherapy Lymphoma-type (CHOP), sarcoma-type (ifosfamide, doxorubicin) or gemcitabine with docetaxel; responses vary (Jain et al., 2017)
Immunotherapy Many tumours express PD-L1; checkpoint inhibitors have helped some patients
Targeted therapy Being explored, for example BRAF inhibitors for BRAF V600E tumours
Clinical trials Recommended where available

What treatment involves day to day

Part of treatment What to expect
Surgery for a neck node or tonsil Usually a short hospital stay; most people eat and talk normally within days to weeks
Abdominal surgery A larger operation with a hospital stay of about 1 week and a recovery of several weeks
Radiotherapy Short daily sessions on weekdays, usually over 5-6 weeks
Chemotherapy Given through a drip in cycles every 2-3 weeks, usually as a day patient
Immunotherapy A drip every 3-6 weeks, with regular blood tests to check for side effects

Side effects

Treatment Possible side effects
Neck or throat surgery Pain, swallowing difficulty, voice change, numbness
Abdominal surgery Pain, slow recovery of bowel function, wound problems
Radiotherapy Skin soreness, tiredness; dry mouth or sore throat in the head and neck area
Chemotherapy Low blood counts, infections, nausea, hair loss, tiredness
Immunotherapy Tiredness, rash, and inflammation of the bowel, lungs, liver or glands

7. Outlook (prognosis)

Measure Approximate figures
Local recurrence About 1 in 4 to 1 in 3
Distant spread About 1 in 4, sometimes many years later
Long-term survival Most people with localised disease are alive several years after treatment

A pooled analysis of 462 cases confirmed that recurrence and spread are common, and that complete surgery is linked with the best results (Saygin et al., 2013). Chan and colleagues first showed that the tumour behaves more aggressively than once thought, and described features linked with a worse outcome (Chan et al., 1997). A large single-centre study found that outcomes varied widely and that many patients with localised disease lived for years (Jain et al., 2017).

Factors linked with a poorer outlook

  • Tumour larger than 6 cm
  • Abdominal location
  • Coagulative necrosis
  • High mitotic rate (many dividing cells)
  • Marked cell atypia
  • Incomplete removal

The EBV-positive inflammatory type in the liver or spleen usually behaves in a more indolent way.

8. Follow-up

Follow-up Purpose
Clinical examination Every 3-6 months for the first few years
CT, MRI or PET-CT To detect recurrence at the original site or spread
Long-term checks Continued for at least 5-10 years, because late recurrences occur

9. Living with follicular dendritic cell sarcoma

  • Keep all follow-up appointments, even if you feel well
  • Check for new lumps in the neck, armpits and groin
  • Report new symptoms such as cough, swallowing problems or tummy pain
  • Ask for swallowing and speech therapy after head and neck treatment if needed
  • Look after your mouth and teeth after radiotherapy to the throat
  • Stay active with regular walking or gentle exercise to help recovery and energy levels
  • Stop smoking, which improves healing and reduces the side effects of radiotherapy
  • Seek support from rare cancer and sarcoma charities

10. Frequently asked questions

Question Answer
Is FDC sarcoma a lymphoma? No. It arises in lymphoid tissue but from support (stromal) cells, not lymphocytes
Is it the same as follicular lymphoma? No. Follicular lymphoma is a B-cell cancer; the names are similar because both relate to lymph node follicles
Is it inherited? No
Will I need chemotherapy? Usually not if the tumour can be fully removed
Can it come back? Yes, sometimes years later, so follow-up is important
Is it linked to Castleman disease? In some people, yes
Why did the diagnosis take so long? The tumour is rare and looks like several other cancers, so specialist stains and expert review are often needed
Can I have children after treatment? Surgery and radiotherapy away from the pelvis usually do not affect fertility; ask about fertility preservation before chemotherapy

11. Questions to ask your care team

  • Has the diagnosis been confirmed with CD21, CD23 and CD35 stains?
  • Was the tumour completely removed?
  • Does the tumour have high-risk features?
  • Would radiotherapy reduce my risk of recurrence?
  • How often will I have scans, and for how long?
  • Are there clinical trials I could join?

Resources

  1. Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms’, Leukemia, 36(7), pp. 1720-1748.
  2. Chan, J.K. et al. (1997) ‘Follicular dendritic cell sarcoma: clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized’, Cancer, 79(2), pp. 294-313.
  3. Facchetti, F., Simbeni, M. and Lorenzi, L. (2021) ‘Follicular dendritic cell sarcoma’, Pathologica, 113(5), pp. 316-329.
  4. Griffin, G.K. et al. (2016) ‘Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-kappaB regulatory genes’, Modern Pathology, 29(1), pp. 67-74.
  5. Jain, P. et al. (2017) ‘Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma’, British Journal of Haematology, 178(3), pp. 403-412.
  6. Saygin, C. et al. (2013) ‘Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series’, Critical Reviews in Oncology/Hematology, 88(2), pp. 253-271.
  7. National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.